Drug "Sparflo": okwu

Agwọ ọrịa "Sparflo" na-ezo aka na-adakarị na pharmacological antibacterial otu (fluoroquinol). Dị ọgwụ na mbadamba nke 200 mg. N'ọrụ umi - sparfloxacin. E auxiliaries: ya ọka starch, crospovidone, microcrystalline cellulose, magnesium stearate na sịlịkọn dioxide. Shei mejupụtara agụnye propylene glycol, talc, titanium dioxide.

Ọgwụ nje "Sparflo" bụ a ọgwụ ngwaahịa na a dịgasị iche iche. Na-akwanyere gram-mma bacteria hụrụ elu ọrụ nke mbadamba "Sparflo". Guide akọwa megide gram-adịghị mma bacteria na-adịghị mkpa ọrụ.

Absorption nke sparfloxacin na-eme nnọọ nwayọọ nwayọọ site digestive tract. Ya kacha ịta na ahụ a na-enweta mgbe a kacha nke 6 awa na zuru bioavailability - 92%, na absorption nke ọgwụ adịghị emetụta nri. Extrarenal ndọrọ ego na-adị site na banyere 60% "Sparflo" nkwadebe. Guide na-egosi na kacha mmepụta oge dị ruo 20 awa.

Otu n'ime ihe ndị na-egosi maka ojiji "Sparflo" ọgwụ ndu na-egosi ndị na-esonụ pathologies:

- na-efe efe nke elu akụkụ okuku ume na tract, dị ka purulent Sinusitis, mastoiditis, otitis media;

- akụkụ okuku ume na-efe efe dị ka oyi baa, ala ala akpa ume ọrịa;

- Shigellosis;

- akpụkpọ na-efe efe dị ka ahụ etuto, furunculosis, cellulitis, pyoderma, etc.;

- na-efe efe nke urinary tract na akụrụ. Ndị a gụnyere cystitis, prostatitis, urethritis, pyelonephritis;

- gonorrhea (nnukwu, ala ala);

- na-efe efe nke ịwa ahụ si;

- Chlamydia (laghachiri nnukwu ụdị).

"Sparflo" na-adabere na onunu ogwu ogo nke ọrịa. Ntuziaka maka ojiji na-atụ aro n'ụbọchị mbụ ochichi nke 400 mg nke ọgwụ ọnụ otu ugboro, n'agbanyeghị nke nri. Site na nke abụọ ụbọchị - 200 mg kwa ụbọchị. Si pụta bacteriological nnyocha, na-adakarị N'ezie na ogo nke ọrịa kpebisiri na oge nke ọgwụgwọ.

Si digestive usoro nwere mmetụta na-emepụta ruru n'ikuku "Sparflo" nkwadebe. Ntụziaka akpọ ekwe omume nke afọ ọsịsa, vomiting na ọgbụgbọ. E nwere mmetụta ọjọọ na Central ụjọ usoro, ha na-egosipụta ụdị ehighị ụra nke ọma na isi ọwụwa. Atralgiya, myalgia bụ n'ihi mmetụta na nweekwa usoro.

N'ụzọ dị mwute, a ọgwụ nwere contraindications. Nke a bụ ikpe nke hypersensitivity na-arụsi ọrụ ike umi, ụmụ n'okpuru afọ 15 na glucose-6-fosfatdigidrogenazy ọdịda. Na e nwere ike contraindication maka ewere ọgwụ "Sparflo" ime na lactating inyom. Esonụ pụrụ iche ntụziaka ntuziaka ekwesịghị ịbụ n'oge na mgbe ọgwụgwọ (banyere 5 ụbọchị) ikpughe ozu ultraviolet radieshon. Na obere okwu, e nwere gusts nke akwara, mgbe ọ na-achọpụta rụọ na i kwesịrị ozugbo kwụsị ịṅụ ọgwụ ọjọọ.

Ugbu a, ọ dịghị ihe ngwọta na-hụrụ na ikpe nke ọgwụ ovadozu "Sparflo" ma na-atụ aro symptomatic ọgwụ, hemodialysis.

I kwesịrị ịmata nke na mmekọrịta nke nọ n'ọrụ umi, akpan akpan sparfloxacin, na ndị ọzọ ọgwụ. Ọrịa na-ewere terfenadine, erythromycin, astemizole, ya bụ, ego na-enyere dịkwuo QT-nkeji, ọgwụ na-contraindicated, n'ihi na ọ na-bụ nke usoro isiokwu a nke ọgwụ.

Imekotaotuugbo ọgwụgwọ na ọgwụ, "Sparflo" na theophylline emetụtaghị ya pharmacokinetics, ọ gaghị ekwe omume na-ekwu banyere ferrous sulfate, antacids. Ha na usoro a ga-rụrụ na etiti oge nke 2 awa site n'ikuku Sparflo. Sparfloxacin nkesa adịghị emetụta cimetidine. Accelerates ya absorption tsizaprit, enweghị na-emetụta ya bioavailability.